Sep 30 2026 11:05 PM EST

Sep 30 2026

AI‑Centric Data‑Center and Biotech Catalysts Drive Winners as Financial Weakness Saps Losers

Over the past five trading sessions, Chindata Group Holdings Limited (CD.US) rallied ~29% and Ginkgo Bioworks Holdings, Inc. (DNA.US) rose ~17%, while Cullinan Oncology, Inc. (CGEM.US) fell ~30.6%, Alkami Technology (ALKT.US) slipped ~19%, and Ocean Power Technologies (OPTT.US) continued an 83% six‑month decline. The moves reflect a split between companies benefiting from AI‑driven data‑center spending and biotech partnership activity, versus those wrestling with cash‑flow constraints, earnings misses and heightened interest‑rate pressure.

Quantum’s fiscal Q4 2026 revenue of $78.0 million beat guidance, delivering its first positive adjusted EBITDA since 2025 at $1.0 million. Chindata’s balance sheet now shows a current ratio of 27.53 and debt‑to‑equity of 0.02, supporting a rapid cap‑ex rollout in China’s AI‑intensive data‑center market. Ginkgo announced a $47 million, 97‑instrument deal with Pacific Northwest National Laboratory and a $17.5 million ARPA‑H subcontract, triggering short‑squeeze activity that lifted its stock. By contrast, Ocean Power reported a net loss of $48.9 million for FY2026 and a going‑concern warning, while Cullinan posted a modest EPS beat but disclosed three deaths in its zipalertinib trial, prompting a sharp sell‑off. Alkami missed consensus EPS of $0.15, posting ‑$0.08, and walked away from a potential buyout, eroding its valuation.

AI‑Centric Data‑Center Winners

Quantum’s refreshed high‑density storage portfolio, highlighted by the LTO‑10 tape drive and Scalar i7 RAPTOR delivering up to 60 PB per rack, is positioned to capture the video‑surveillance market, which is expanding at a 21.7% CAGR and projected to reach $84.5 billion by 2030. The company’s debt reduction—from $102.5 million to $55.9 million—and a $90.0 million convertible note issuance reinforced its balance sheet, prompting analysts to upgrade the stock to Zacks Rank #2.

In China, Chindata’s modular, GPU‑ready pods target the “ultra‑dense, low‑latency” AI compute demand that CBRE expects to grow 61% in 2026. The company’s assets rose to $50.86 million and cash‑flow‑supporting financing inflows reached $13.8 million, underpinning a 28.8% price gain despite a three‑month return of –16.7%.

Biotech Momentum and Short‑Squeeze Activity

Ginkgo’s autonomous‑lab contracts are expected to shift revenue toward higher‑margin SaaS licensing. The $47 million Pacific Northwest National Laboratory deal and new autonomous labs at Novo’s Waltham R&D site, together with collaborations that could generate up to $406 million with Boehringer Ingelheim, underpin the stock’s rally. Short interest surged from 7.3 million to 18.6 million shares, compressing the available short‑sale pool and prompting a short‑covering squeeze that contributed to the 15% single‑day jump on September 10.

Financial Weakness and Earnings Misses Draggers

Ocean Power’s FY2026 net loss of $48.9 million and negative free cash flow of $24.8 million were highlighted in an audit that included a going‑concern warning. Despite a record backlog of $19.8 million, the company raised $28.7 million through equity and convertible note offerings, diluting existing shareholders and prompting a 1‑for‑30 reverse split.

Cullinan posted an EPS of ‑0.81, beating the consensus of ‑0.82, but a September 15 filing disclosed three patient deaths in the zipalertinib trial, raising safety concerns ahead of an FDA filing. The company’s trailing‑12‑month return on equity of ‑50.3% and undisclosed cash runway left investors wary amid a Federal Reserve rate hike to the 3.75%–4.00% range.

Alkami’s Q2 2026 revenue of $129.84 million beat estimates, and adjusted EBITDA improved to $19.4 million (margin 14.9%). However, EPS of ‑$0.08 missed the consensus of $0.15, and the board’s decision to reject a buyout removed a potential liquidity event. JPMorgan downgraded the stock to Underweight with a new price target of $14, and short interest rose to 6.67 million shares (7.5% of float).

Market Implications

The five‑day price swings underscore a market that is rewarding companies that can demonstrate tangible progress in AI‑driven infrastructure and biotech automation, while penalizing those whose financial health remains precarious. Continued acceleration of AI workloads in data‑center construction should sustain demand for high‑density storage and modular compute, benefitting Quantum and Chindata. In biotech, the translation of autonomous‑lab contracts into recurring revenue will be the key test for Ginkgo, especially as analysts have already trimmed price targets.

Conversely, firms such as Ocean Power, Cullinan and Alkami must address cash‑burn, regulatory scrutiny and earnings volatility to reverse the current downtrend. The next quarter’s earnings releases and regulatory filings—particularly Cullinan’s upcoming FDA filing for zipalertinib and Quantum’s Q1 2027 guidance—will be pivotal in determining whether the recent moves represent a lasting re‑rating or a short‑term correction.